Literature DB >> 17178988

Keratosis pilaris rubra: a common but underrecognized condition.

Ann L Marqueling1, Amy E Gilliam, Julie Prendiville, Alex Zvulunov, Richard J Antaya, Jeffrey Sugarman, Mei-Lin Pang, Phillip Lee, Lawrence Eichenfield, Brandie Metz, Gerald N Goldberg, Roderic J Phillips, Ilona J Frieden.   

Abstract

BACKGROUND: Keratosis pilaris is a common skin disorder of childhood that often improves with age. Less common variants of keratosis pilaris include keratosis pilaris atrophicans and atrophodermia vermiculata. OBSERVATIONS: In this case series from dermatology practices in the United States, Canada, Israel, and Australia, the clinical characteristics of 27 patients with keratosis pilaris rubra are described. Marked erythema with follicular prominence was noted in all patients, most commonly affecting the lateral aspects of the cheeks and the proximal arms and legs, with both more marked erythema and widespread extent of disease than in keratosis pilaris. The mean age at onset was 5 years (range, birth to 12 years). Sixty-three percent of patients were male. No patients had atrophy or scarring from their lesions. Various treatments were used, with minimal or no improvement in most cases.
CONCLUSIONS: Keratosis pilaris rubra is a variant of keratosis pilaris, with more prominent erythema and with more widespread areas of skin involvement in some cases, but without the atrophy or hyperpigmentation noted in certain keratosis pilaris variants. It seems to be a relatively common but uncommonly reported condition.

Entities:  

Mesh:

Year:  2006        PMID: 17178988     DOI: 10.1001/archderm.142.12.1611

Source DB:  PubMed          Journal:  Arch Dermatol        ISSN: 0003-987X


  1 in total

Review 1.  Keratosis pilaris rubra successfully treated with topical sirolimus: Report of a case and review of the literature.

Authors:  Alexandra Eckburg; Tiana Kazemi; Sheilagh Maguiness
Journal:  Pediatr Dermatol       Date:  2022-03-01       Impact factor: 1.997

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.